Pharma Companies

Laurus Labs zooms 73% in 2025, hits new high; what's driving pharma stock?

Laurus Labs management said the fundamentals of the company's business remain strong, with sustained growth momentum in the Contract Development and Manufacturing Organization and Generic business.

RPG Life Sciences eyes GLP-1 entry, US market via plant acquisitions

The company sharpens its domestic specialty formulations focus and looks to scale APIs through acquisitions, while planning partnership-led GLP-1 launches

Biocon to integrate Biocon Biologics in $5.5-bn tranx, pivots away from IPO

Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group structure, and strengthening the consolidated balance sheet

Biocon to make Biocon Biologics a wholly owned subsidiary in $5.5 bn deal

Biocon Biologics Chief Executive Shreehas Tambe will become CEO and managing director of the combined entity post-integration

Cipla launches India's first integrated lung diagnostics, wellness centre

The Delhi facility offers over 60 advanced tests and aims to close critical gaps in respiratory diagnosis and care

Apollo Pharmacy targets 100 mn customers in 5 yrs, 2 new stores daily: CEO

Apollo Pharmacy plans to open two new stores every day, targeting to grow its customer base to 10 crore within the next five years, its CEO P Jayakumar said on Friday. The omni-channel pharmacy network, which has crossed the 7,000-store mark with the opening of its latest store in Ayodhya, Uttar Pradesh, aims to strengthen the neighbourhood pharmacy reach. "We will continue to expand by opening two new stores every day and grow our customer base to 100 million within the next five years, ensuring that the highest-quality medicines remain within everyone's reach," Jayakumar said in a statement. Apollo HealthCo operates Apollo Pharmacy that serves users across over 19,000 pin codes. Apollo HealthCo Executive Chairperson Shobana Kamineni said at present, Apollo Pharmacy serves over one million orders every day. "The 7,000-store milestone reflects the scale Apollo has built and the trust families place in us. We will continue to deepen access, strengthen India's neighbourhood pharmacy

Aurobindo incurring loss at China Plant, hopes to achieve break-even by Q4

Aurobindo Pharma is currently incurring a loss at its China-based facility and expects the plant to achieve break-even by the end of the fiscal year, according to its CFO S Subramanian. The Hyderabad-based drug major remains confident about sustaining its growth momentum and driving value creation across all businesses, he said. "China (plant), as on date in the quarter, I will be incurring a loss of around maybe a million dollars, but, probably, we will be able to achieve the break-even between Q3 and Q4 and after that, China will start moving up in the overall contributing to the growth of the EBITDA growth," Subramanian said in an analyst call. The oral-solid-dosage (OSD) facility in China continues to ramp up, advancing towards the capacity of two billion, backed by European approval of ten products and three local product approvals, he stated. The site is on track to deliver EBITDA break-even by Q3-Q4 FY26, reinforcing its strategic importance to the global network, he added.

Sudeep Pharma IPO opens Nov 21: Know key strengths, risks before you invest

Sudeep Pharma IPO will be offered at a price band of ₹563 to ₹593 per share

Sudeep Pharma IPO opens Nov 21; sets price band at ₹549-577; Check details

Sudeep Pharma IPO will open for public bidding on Friday, November 21 and close on Tuesday, November 25, 2025

Centre brings draft rules to debar drugmakers who provide fake information

The health ministry proposes new provisions under the Drugs Rules, 1945, allowing regulators to bar applicants who submit fake or misleading data for approvals

Biocon Biologics gets Health Canada approval for Yesintek, Yesintek I.V.

The approval of Yesintek and Yesintek I.V., biosimilars to Stelara, strengthens Biocon Biologics' presence in North America and expands its immunology portfolio

Glenmark recalls product in US over manufacturing issue: USFDA

Drugmakers Glenmark and Dr Reddy's Laboratories are recalling products in the US due to manufacturing issues, according to the US Food and Drug Administration (USFDA). As per its latest Enforcement Report, the US health regulator noted that a US-based unit of Glenmark Pharmaceuticals is recalling 26,928 packs of oral contraceptive medication in the US. Mahwah, New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the affected lot of Viorele, Desogestrel and Ethinyl Estradiol (USP, 0.15 mg/ 0.02 mg) and Ethinyl Estradiol tablets due to "failed impurities/degradation specifications." The affected lot was produced at Mumbai-headquartered drug maker's Goa manufacturing facility. The drug firm issued the Class II nationwide recall on September 3, 2025. USFDA stated that a US-based subsidiary of Dr Reddy's Laboratories is recalling the medication used to provide muscle relaxation during surgery. Princeton, New Jersey-based Dr. Reddy's Laboratories, Inc is recalling 571 vials o

Centre refuses deadline extension for pharma firms after Coldrif deaths

The decision to turn down requests from drug manufacturers for more time came after it was highlighted that Sresan Pharmaceutical, the company that produced Coldrif, did not upgrade its facilities

Graph AI raises $3 mn from Bessemer to target $8 bn drug safety market

California-based Graph AI raised $3 million in seed funding led by Bessemer Venture Partners to scale its AI-driven pharmacovigilance platform for global drug safety and compliance

WHO alert on 3 'toxic' syrups: Which pharma companies are under the scanner?

The World Health Organization has issued a global alert after identifying three toxic cough syrups in India that have been linked to the deaths of several children in Madhya Pradesh and Rajasthan.

Last day! Rubicon Research IPO ends today; subscription up 28x, NIIs lead

Rubicon Research's unlisted shares were trading at ₹580, reflecting a grey market premium of ₹95 or 19.6 per cent above the issue price of ₹485

Cough syrup deaths: Probe into Coldrif manufacturer exposes TNFDA lapses

The investigation against the Kanchipuram-based manufacturer of Coldrif cough syrup, linked to the deaths of children in Madhya Pradesh, has brought to light lapses by the Tamil Nadu Food and Drug Administration in enforcing basic regulatory norms, CDSCO sources said. Licensed in 2011 by the Tamil Nadu Food and Drug Administration (TNFDA), Sresan Pharma continued operations unchecked for over a decade despite its dismal infrastructure and multiple violations of national drug safety rules, they said. A recent inspection by the Central Drugs Standard Control Organisation (CDSCO) exposed the unit's appalling conditions and total non-compliance with Good Manufacturing Practices (GMP), the sources said. "The CDSCO has not been involved in any of the audits at Sresan Pharma. Since the CDSCO was not involved and the state FDA did not inform the CDSCO about this company in any way, this company was not part of any of the CDSCO databases," a source said. TNFDA officials could not be reached

AstraZeneca to strike landmark drug price deal with Trump administration

The deal is expected to be announced at the White House on Friday, said the people, who spoke on condition of anonymity because the plans are not yet public

Lupin gets USFDA nod for generic cancer drug Lenalidomide capsules

Lupin has received USFDA approval for generic Lenalidomide capsules in six strengths, adding to competition in the US oncology market for Bristol-Myers Squibb's Revlimid

Mankind joins hands with OpenAI to institutionalise AI in operations

"GPT-powered dashboards will be used to provide real-time, data-driven insights across R&D, supply chain and commercial operations," a company executive told Business Standard